Resonance Health Ltd
Company Profile
Business description
Resonance Health Ltd is engaged in the development and commercialisation of software-as-a-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used to assess liver iron. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are: SaMD, which derives key revenue; Corporate; TrialsWest; and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America and the Europe, Middle East, and Africa (EMEA) regions.
Contact
141 Burswood Road
Level 1
Burswood
PerthWA6100
AUST: +61 892865300
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
Employees
18
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,144.70 | 189.80 | 2.12% |
| CAC 40 | 8,131.85 | 73.52 | -0.90% |
| DAX 40 | 25,799.91 | 525.10 | -1.99% |
| Dow JONES (US) | 51,470.23 | 52.83 | -0.10% |
| FTSE 100 | 10,645.39 | 137.27 | -1.27% |
| HKSE | 24,481.86 | 562.36 | 2.35% |
| NASDAQ | 24,615.59 | 300.60 | 1.24% |
| Nikkei 225 | 57,434.77 | 4,753.86 | -7.64% |
| NZX 50 Index | 13,998.50 | 92.47 | -0.66% |
| S&P 500 | 7,403.27 | 49.54 | 0.67% |
| S&P/ASX 200 | 9,020.80 | 186.30 | 2.11% |
| SSE Composite Index | 3,649.18 | 40.73 | -1.10% |